- Home
- QSI vs PLRX Comparison
QSI vs PLRX Comparison
Compare QSI & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QSI | PLRX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 79.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | QSI | PLRX |
|---|---|---|
| Price | $0.97 | $1.35 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | $1.00 | ★ $2.50 |
| AVG Volume (30 Days) | ★ 3.0M | 601.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $196.35 | N/A |
| Revenue Next Year | $229.03 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.84 | $1.09 |
| 52 Week High | $3.10 | $1.95 |
Technical Indicators
Market Signals| Indicator | QSI | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.07 | 56.83 |
| Support Level | $0.90 | $1.12 |
| Resistance Level | $1.03 | $1.36 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 48.88 | 55.81 |
Price Performance
Historical ComparisonAbout QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.